Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pirtobrutinib · Jaypirca, LY-3527727

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Loxo Oncol

Approved FDA, Jan 2023

LLY Developer

1 Registered trials

What is Pirtobrutinib?

Pirtobrutinib is a small molecule, noncovalent inhibitor of Bruton's tyrosine kinase (BTK), binding both wild type BTK and BTK with C481 mutations. It blocks BTK signaling in the B-cell antigen receptor and cytokine receptor pathways that drive malignant B-cell proliferation. It is used in mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Jaypirca, LY-3527727, Loxo-305
Drug type: Small molecule
Targets: Bruton's tyrosine kinase (BTK)
Mechanism: Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways: B-cell antigen receptor signaling, cytokine receptor signaling, B-cell proliferation, trafficking, chemotaxis and adhesion
Therapy area: Hematology, Immunology
Developer: Loxo Oncol (LLY)
FDA status: Approved as Jaypirca (January 27, 2023), NDA216059 · FDA label
UNII: JNA39I7ZVB

✅ FDA-approved uses

Mantle cell lymphoma
Chronic lymphocytic leukemia or small lymphocytic lymphoma

From the indications section of the FDA label (version of Mar 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06721013	Phase 1/2	Immune Thrombocytopenia (ITP)	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Immune Thrombocytopenia (ITP)

Other drugs acting on BTK

Acalabrutinib FDA approved Zanubrutinib FDA approved APG-3288 Phase 1

More from Loxo Oncol

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Pirtobrutinib

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z